Luveltamab tazevibulin
REFRαME P1
Phase 2 small_molecule terminated
Quick answer
Luveltamab tazevibulin for Acute Myeloid Leukemia (AML) is a Phase 2 program (small_molecule) at SUTRO BIOPHARMA, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- SUTRO BIOPHARMA, INC.
- Indication
- Acute Myeloid Leukemia (AML)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated